Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment
Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment
复制标题
DOI：
10.1016/j.jns.2009.07.026
复制
发表时间：
2009-12-15
影响因子：
4.4
通讯作者：
Jeon, Beom S.
中科院分区：
文献类型：
--
作者：
Kim, Han-Joon;Park, So-Young;Jeon, Beom S.
背景：非运动症状（NMSs）在帕金森病（PD）患者中很常见，但对新发PD患者的全系列NMSs负担知之甚少。目的：使用非运动症状评估量表（NMSs）对未经治疗的PD患者的NMSs进行定量和定性评估；研究人员将研究结果与对照组进行了比较。多巴胺能处理对NMSs的影响也被确定。方法：对23例未经治疗的PD患者和23例健康对照进行NMSs评估。同时对PD患者进行统一帕金森病评定量表（mUPDRS）运动部分和Hoehn and Yahr （HY）分期检查。比较PD患者的NMSs数和NMSs评分。在开始多巴胺能药物治疗3个月后，对16例PD患者的NMSS和mUPDRS以及HY期进行了重新评估。结果：PD患者NMSs数量和NMSs评分均显著高于对照组。PD患者中最常见的三种NMSs是“夜尿症”、“忘记事情或事件”和“不宁腿”。在PD组中，NMSs的数量与HY分期相关，但与年龄、病程或mUPDRS评分无关。在开始PD治疗3个月后对16例患者的随访显示，尽管运动症状有所改善，但NMSs的数量和NMSs评分均未发生变化。结论：未经治疗的PD患者比对照组有更多的非运动问题，这些NMSs并没有通过多巴胺能药物得到改善。(C) 2009 Elsevier B.V.版权所有
Background: Nonmotor symptoms (NMSs) are common in patients with Parkinson disease (PD), but little is known about the burden of the full range of NMSs in de novo PD patients.Objectives: NMSs in untreated de novo PD patients were evaluated both quantitatively and qualitatively using the Non-Motor Symptoms Assessment Scale (NMSS); the findings were compared to those of control subjects. The effects of dopaminergic treatment on NMSs were also determined.Methods: NMSs were evaluated in 23 patients with untreated de novo PD and 23 healthy controls. The motor section of the Unified Parkinson Disease Rating Scale (mUPDRS) and the Hoehn and Yahr (HY) stage were also checked in the PD patients. The number of NMSs and the NMSS scores of the PD patients were compared with those of the controls. Three months after the start of dopaminergic medication, 16 PD patients were reevaluated with respect to the NMSS and mUPDRS, and the HY stage.Results: The number of NMSs and the NMSS scores were significantly higher in the PD patients than in the controls. The three most prevalent NMSs among the PD patients were 'nocturia,' 'forget things or events,' and 'restless legs.' In the PD group, the number of NMSs was correlated with the HY stage but not with age, disease duration, or mUPDRS score. Follow-up of 16 patients at 3 months after commencing PD medication revealed no changes in either the number of NMSs or the NMSS score, despite improvement in motor symptoms.Conclusions: Untreated de novo PD patients have more nonmotor problems than controls, and these NMSs are not ameliorated by dopaminergic medication. (C) 2009 Elsevier B.V. All rights reserved.